COR

SEC source: 0001140859-23-000157 · wk-form4_1699911063.xml · nonDerivative · entry 4

Campbell Elizabeth S · CIK 0001882641 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,843.851

F4 · kind: Satisfaction of tax withholding obligation incident to the vesting of restricted stock units.

SEC source: 0001140859-23-000157 · wk-form4_1699911063.xml · nonDerivative · entry 3

Campbell Elizabeth S · CIK 0001882641 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,779.851

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · price: Grant of restricted stock units received for no consideration that vest in three equal annual installments on 11/9/2023, 11/9/2024, and 11/9/2025.

SEC source: 0001140859-23-000157 · wk-form4_1699911063.xml · nonDerivative · entry 2

Campbell Elizabeth S · CIK 0001882641 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,756.851

F2 · kind: Satisfaction of tax withholding obligation incident to the vesting of performance share units.

SEC source: 0001140859-23-000157 · wk-form4_1699911063.xml · nonDerivative · entry 1

Campbell Elizabeth S · CIK 0001882641 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,447.851

F1 · price: Shares were received for no consideration upon the satisfaction of performance criteria underlying an award of performance share units.

SEC source: 0001140859-23-000155 · wk-form4_1699910900.xml · derivative · entry 5

Battaglia Silvana · CIK 0001774724 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,529

Underlying: Common Stock · 1,264 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Grant of restricted stock units received for no consideration that vest in three equal annual installments on 11/9/2023, 11/9/2024, and 11/9/2025.

F3 · price: Grant of restricted stock units received for no consideration that vest in three equal annual installments on 11/9/2023, 11/9/2024, and 11/9/2025.

F3 · derivative.exercise_date: Grant of restricted stock units received for no consideration that vest in three equal annual installments on 11/9/2023, 11/9/2024, and 11/9/2025.

F3 · derivative.expiration_date: Grant of restricted stock units received for no consideration that vest in three equal annual installments on 11/9/2023, 11/9/2024, and 11/9/2025.

SEC source: 0001140859-23-000155 · wk-form4_1699910900.xml · nonDerivative · entry 4

Battaglia Silvana · CIK 0001774724 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,359.817

F4 · kind: Satisfaction of tax withholding obligation incident to the vesting of restricted stock units.

SEC source: 0001140859-23-000155 · wk-form4_1699910900.xml · nonDerivative · entry 3

Battaglia Silvana · CIK 0001774724 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 19,909.817

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · price: Grant of restricted stock units received for no consideration that vest in three equal annual installments on 11/9/2023, 11/9/2024, and 11/9/2025.

SEC source: 0001140859-23-000155 · wk-form4_1699910900.xml · nonDerivative · entry 2

Battaglia Silvana · CIK 0001774724 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,645.817

F2 · kind: Satisfaction of tax withholding obligation incident to the vesting of performance share units.

SEC source: 0001140859-23-000155 · wk-form4_1699910900.xml · nonDerivative · entry 1

Battaglia Silvana · CIK 0001774724 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,743.817

F1 · price: Shares were received for no consideration upon the satisfaction of performance criteria underlying an award of performance share units.

SEC source: 0000899243-23-020341 · doc4.xml · derivative · entry 5

Walgreens Boots Alliance, Inc. · CIK 0001618921 · 10% owner

Walgreens Boots Alliance Holdings LLC · CIK 0001669077 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 540,000

Underlying: Common Stock · 540,000 shares

Expires not disclosed

F2 · derivative.exercise_price: On November 9, 2023, Walgreens Boots Alliance Holdings LLC ("Counterparty"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the "Reporting Person"), entered into variable pre-paid forward sale contracts (the "Contracts") with four unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 2,700,000 shares of common stock ("Common Stock") of Cencora, Inc. (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $423.9 million on or about the date of entering into the Contracts.

F3 · derivative.exercise_price: [continued from FN (2)] Counterparty also pledged 2,700,000 shares of Common Stock (the "Pledged Shares") in the aggregate to the financial institutions or their affiliates to secure its obligations under the Contracts and retained certain dividend and voting rights on the Pledged Shares. In respect of each valuation date under the Contracts, the aggregate number of shares of Common Stock to be delivered to the financial institutions or cash to be delivered to (or by) the financial institutions is to be determined as follows: Counterparty may, at its election, subject to certain conditions (1) be obligated to deliver to the financial institutions the full number of shares to which such valuation date relates and will receive an additional cash payment determined as follows:

F4 · derivative.exercise_price: [continued from FN (3)] (a) if the volume-weighted average price of the Common Stock on such valuation date (the "Reference Price") is less than or equal to $173.8838 (the "Floor Price"), the additional cash payment would be zero, (b) if the Reference Price is greater than the Floor Price but less than or equal to $224.6813 (the "Cap Price"), the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Reference Price over the Floor Price and (c) if the Reference Price is greater than the Cap Price, the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Cap Price over the Floor Price. Alternatively, (2) Counterparty may elect, subject to certain conditions, to not receive any additional cash payment and be obligated to deliver to the financial institutions in the aggregate a number of shares of Common Stock

F5 · derivative.exercise_price: [continued from FN (4)] (or the cash value thereof at the Reference Price) determined as follows: (a) if the Reference Price is less than or equal to the Floor Price, the full number of shares to which such valuation date relates, (b) if the Reference Price is greater than the Floor Price but less than or equal to the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the Floor Price and (c) if the Reference Price is greater than the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the sum of the Floor Price and the excess of the Reference Price over the Cap Price.

F6 · derivative.exercise_price: The Contracts are scheduled to mature evenly over a series of 20 valuation dates from June 1, 2026 to June 29, 2026, inclusive.

F2 · kind: On November 9, 2023, Walgreens Boots Alliance Holdings LLC ("Counterparty"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the "Reporting Person"), entered into variable pre-paid forward sale contracts (the "Contracts") with four unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 2,700,000 shares of common stock ("Common Stock") of Cencora, Inc. (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $423.9 million on or about the date of entering into the Contracts.

F2 · price: On November 9, 2023, Walgreens Boots Alliance Holdings LLC ("Counterparty"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the "Reporting Person"), entered into variable pre-paid forward sale contracts (the "Contracts") with four unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 2,700,000 shares of common stock ("Common Stock") of Cencora, Inc. (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $423.9 million on or about the date of entering into the Contracts.

F2 · derivative.exercise_date: On November 9, 2023, Walgreens Boots Alliance Holdings LLC ("Counterparty"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the "Reporting Person"), entered into variable pre-paid forward sale contracts (the "Contracts") with four unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 2,700,000 shares of common stock ("Common Stock") of Cencora, Inc. (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $423.9 million on or about the date of entering into the Contracts.

F3 · derivative.exercise_date: [continued from FN (2)] Counterparty also pledged 2,700,000 shares of Common Stock (the "Pledged Shares") in the aggregate to the financial institutions or their affiliates to secure its obligations under the Contracts and retained certain dividend and voting rights on the Pledged Shares. In respect of each valuation date under the Contracts, the aggregate number of shares of Common Stock to be delivered to the financial institutions or cash to be delivered to (or by) the financial institutions is to be determined as follows: Counterparty may, at its election, subject to certain conditions (1) be obligated to deliver to the financial institutions the full number of shares to which such valuation date relates and will receive an additional cash payment determined as follows:

F4 · derivative.exercise_date: [continued from FN (3)] (a) if the volume-weighted average price of the Common Stock on such valuation date (the "Reference Price") is less than or equal to $173.8838 (the "Floor Price"), the additional cash payment would be zero, (b) if the Reference Price is greater than the Floor Price but less than or equal to $224.6813 (the "Cap Price"), the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Reference Price over the Floor Price and (c) if the Reference Price is greater than the Cap Price, the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Cap Price over the Floor Price. Alternatively, (2) Counterparty may elect, subject to certain conditions, to not receive any additional cash payment and be obligated to deliver to the financial institutions in the aggregate a number of shares of Common Stock

F5 · derivative.exercise_date: [continued from FN (4)] (or the cash value thereof at the Reference Price) determined as follows: (a) if the Reference Price is less than or equal to the Floor Price, the full number of shares to which such valuation date relates, (b) if the Reference Price is greater than the Floor Price but less than or equal to the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the Floor Price and (c) if the Reference Price is greater than the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the sum of the Floor Price and the excess of the Reference Price over the Cap Price.

F6 · derivative.exercise_date: The Contracts are scheduled to mature evenly over a series of 20 valuation dates from June 1, 2026 to June 29, 2026, inclusive.

F2 · derivative.expiration_date: On November 9, 2023, Walgreens Boots Alliance Holdings LLC ("Counterparty"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the "Reporting Person"), entered into variable pre-paid forward sale contracts (the "Contracts") with four unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 2,700,000 shares of common stock ("Common Stock") of Cencora, Inc. (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $423.9 million on or about the date of entering into the Contracts.

F3 · derivative.expiration_date: [continued from FN (2)] Counterparty also pledged 2,700,000 shares of Common Stock (the "Pledged Shares") in the aggregate to the financial institutions or their affiliates to secure its obligations under the Contracts and retained certain dividend and voting rights on the Pledged Shares. In respect of each valuation date under the Contracts, the aggregate number of shares of Common Stock to be delivered to the financial institutions or cash to be delivered to (or by) the financial institutions is to be determined as follows: Counterparty may, at its election, subject to certain conditions (1) be obligated to deliver to the financial institutions the full number of shares to which such valuation date relates and will receive an additional cash payment determined as follows:

F4 · derivative.expiration_date: [continued from FN (3)] (a) if the volume-weighted average price of the Common Stock on such valuation date (the "Reference Price") is less than or equal to $173.8838 (the "Floor Price"), the additional cash payment would be zero, (b) if the Reference Price is greater than the Floor Price but less than or equal to $224.6813 (the "Cap Price"), the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Reference Price over the Floor Price and (c) if the Reference Price is greater than the Cap Price, the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Cap Price over the Floor Price. Alternatively, (2) Counterparty may elect, subject to certain conditions, to not receive any additional cash payment and be obligated to deliver to the financial institutions in the aggregate a number of shares of Common Stock

F5 · derivative.expiration_date: [continued from FN (4)] (or the cash value thereof at the Reference Price) determined as follows: (a) if the Reference Price is less than or equal to the Floor Price, the full number of shares to which such valuation date relates, (b) if the Reference Price is greater than the Floor Price but less than or equal to the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the Floor Price and (c) if the Reference Price is greater than the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the sum of the Floor Price and the excess of the Reference Price over the Cap Price.

F6 · derivative.expiration_date: The Contracts are scheduled to mature evenly over a series of 20 valuation dates from June 1, 2026 to June 29, 2026, inclusive.

F7 · ownership.nature: As previously disclosed, including in the Schedule 13D filed by Walgreen Co. ("Walgreens") and others on April 15, 2014, as amended on January 16, 2015, January 25, 2016, March 22, 2016, August 25, 2016, November 14, 2016, January 6, 2021, June 3, 2021, May 12, 2022, August 4, 2022, November 9, 2022, December 12, 2022, May 15, 2023, June 20, 2023, August 7, 2023 and November 14, 2023, the Form 8-K filed by the Issuer on March 20, 2013, the Form 8-K filed by Walgreens on March 20, 2013, the Form 8-K filed by the Reporting Person on June 4, 2021 and the Form 8-K filed by the Issuer on June 2, 2021, the shares referenced in this Form 4 were acquired in accordance with the Framework Agreement, dated as of March 18, 2013 among Walgreens, Alliance Boots GmbH and the Issuer (the "Framework Agreement").

F8 · ownership.nature: These Contracts are held by Counterparty.

F9 · ownership.nature: As described in the Schedule 13D, as amended, WBA Investments, Inc., a direct wholly-owned subsidiary of the Reporting Person and the sole member of Counterparty, may also be deemed to beneficially own the securities reported in this Form 4.

SEC source: 0000899243-23-020341 · doc4.xml · derivative · entry 4

Walgreens Boots Alliance, Inc. · CIK 0001618921 · 10% owner

Walgreens Boots Alliance Holdings LLC · CIK 0001669077 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 1,080,000

Underlying: Common Stock · 1,080,000 shares

Expires not disclosed

F2 · derivative.exercise_price: On November 9, 2023, Walgreens Boots Alliance Holdings LLC ("Counterparty"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the "Reporting Person"), entered into variable pre-paid forward sale contracts (the "Contracts") with four unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 2,700,000 shares of common stock ("Common Stock") of Cencora, Inc. (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $423.9 million on or about the date of entering into the Contracts.

F3 · derivative.exercise_price: [continued from FN (2)] Counterparty also pledged 2,700,000 shares of Common Stock (the "Pledged Shares") in the aggregate to the financial institutions or their affiliates to secure its obligations under the Contracts and retained certain dividend and voting rights on the Pledged Shares. In respect of each valuation date under the Contracts, the aggregate number of shares of Common Stock to be delivered to the financial institutions or cash to be delivered to (or by) the financial institutions is to be determined as follows: Counterparty may, at its election, subject to certain conditions (1) be obligated to deliver to the financial institutions the full number of shares to which such valuation date relates and will receive an additional cash payment determined as follows:

F4 · derivative.exercise_price: [continued from FN (3)] (a) if the volume-weighted average price of the Common Stock on such valuation date (the "Reference Price") is less than or equal to $173.8838 (the "Floor Price"), the additional cash payment would be zero, (b) if the Reference Price is greater than the Floor Price but less than or equal to $224.6813 (the "Cap Price"), the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Reference Price over the Floor Price and (c) if the Reference Price is greater than the Cap Price, the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Cap Price over the Floor Price. Alternatively, (2) Counterparty may elect, subject to certain conditions, to not receive any additional cash payment and be obligated to deliver to the financial institutions in the aggregate a number of shares of Common Stock

F5 · derivative.exercise_price: [continued from FN (4)] (or the cash value thereof at the Reference Price) determined as follows: (a) if the Reference Price is less than or equal to the Floor Price, the full number of shares to which such valuation date relates, (b) if the Reference Price is greater than the Floor Price but less than or equal to the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the Floor Price and (c) if the Reference Price is greater than the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the sum of the Floor Price and the excess of the Reference Price over the Cap Price.

F6 · derivative.exercise_price: The Contracts are scheduled to mature evenly over a series of 20 valuation dates from June 1, 2026 to June 29, 2026, inclusive.

F2 · kind: On November 9, 2023, Walgreens Boots Alliance Holdings LLC ("Counterparty"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the "Reporting Person"), entered into variable pre-paid forward sale contracts (the "Contracts") with four unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 2,700,000 shares of common stock ("Common Stock") of Cencora, Inc. (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $423.9 million on or about the date of entering into the Contracts.

F2 · price: On November 9, 2023, Walgreens Boots Alliance Holdings LLC ("Counterparty"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the "Reporting Person"), entered into variable pre-paid forward sale contracts (the "Contracts") with four unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 2,700,000 shares of common stock ("Common Stock") of Cencora, Inc. (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $423.9 million on or about the date of entering into the Contracts.

F2 · derivative.exercise_date: On November 9, 2023, Walgreens Boots Alliance Holdings LLC ("Counterparty"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the "Reporting Person"), entered into variable pre-paid forward sale contracts (the "Contracts") with four unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 2,700,000 shares of common stock ("Common Stock") of Cencora, Inc. (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $423.9 million on or about the date of entering into the Contracts.

F3 · derivative.exercise_date: [continued from FN (2)] Counterparty also pledged 2,700,000 shares of Common Stock (the "Pledged Shares") in the aggregate to the financial institutions or their affiliates to secure its obligations under the Contracts and retained certain dividend and voting rights on the Pledged Shares. In respect of each valuation date under the Contracts, the aggregate number of shares of Common Stock to be delivered to the financial institutions or cash to be delivered to (or by) the financial institutions is to be determined as follows: Counterparty may, at its election, subject to certain conditions (1) be obligated to deliver to the financial institutions the full number of shares to which such valuation date relates and will receive an additional cash payment determined as follows:

F4 · derivative.exercise_date: [continued from FN (3)] (a) if the volume-weighted average price of the Common Stock on such valuation date (the "Reference Price") is less than or equal to $173.8838 (the "Floor Price"), the additional cash payment would be zero, (b) if the Reference Price is greater than the Floor Price but less than or equal to $224.6813 (the "Cap Price"), the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Reference Price over the Floor Price and (c) if the Reference Price is greater than the Cap Price, the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Cap Price over the Floor Price. Alternatively, (2) Counterparty may elect, subject to certain conditions, to not receive any additional cash payment and be obligated to deliver to the financial institutions in the aggregate a number of shares of Common Stock

F5 · derivative.exercise_date: [continued from FN (4)] (or the cash value thereof at the Reference Price) determined as follows: (a) if the Reference Price is less than or equal to the Floor Price, the full number of shares to which such valuation date relates, (b) if the Reference Price is greater than the Floor Price but less than or equal to the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the Floor Price and (c) if the Reference Price is greater than the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the sum of the Floor Price and the excess of the Reference Price over the Cap Price.

F6 · derivative.exercise_date: The Contracts are scheduled to mature evenly over a series of 20 valuation dates from June 1, 2026 to June 29, 2026, inclusive.

F2 · derivative.expiration_date: On November 9, 2023, Walgreens Boots Alliance Holdings LLC ("Counterparty"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the "Reporting Person"), entered into variable pre-paid forward sale contracts (the "Contracts") with four unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 2,700,000 shares of common stock ("Common Stock") of Cencora, Inc. (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $423.9 million on or about the date of entering into the Contracts.

F3 · derivative.expiration_date: [continued from FN (2)] Counterparty also pledged 2,700,000 shares of Common Stock (the "Pledged Shares") in the aggregate to the financial institutions or their affiliates to secure its obligations under the Contracts and retained certain dividend and voting rights on the Pledged Shares. In respect of each valuation date under the Contracts, the aggregate number of shares of Common Stock to be delivered to the financial institutions or cash to be delivered to (or by) the financial institutions is to be determined as follows: Counterparty may, at its election, subject to certain conditions (1) be obligated to deliver to the financial institutions the full number of shares to which such valuation date relates and will receive an additional cash payment determined as follows:

F4 · derivative.expiration_date: [continued from FN (3)] (a) if the volume-weighted average price of the Common Stock on such valuation date (the "Reference Price") is less than or equal to $173.8838 (the "Floor Price"), the additional cash payment would be zero, (b) if the Reference Price is greater than the Floor Price but less than or equal to $224.6813 (the "Cap Price"), the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Reference Price over the Floor Price and (c) if the Reference Price is greater than the Cap Price, the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Cap Price over the Floor Price. Alternatively, (2) Counterparty may elect, subject to certain conditions, to not receive any additional cash payment and be obligated to deliver to the financial institutions in the aggregate a number of shares of Common Stock

F5 · derivative.expiration_date: [continued from FN (4)] (or the cash value thereof at the Reference Price) determined as follows: (a) if the Reference Price is less than or equal to the Floor Price, the full number of shares to which such valuation date relates, (b) if the Reference Price is greater than the Floor Price but less than or equal to the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the Floor Price and (c) if the Reference Price is greater than the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the sum of the Floor Price and the excess of the Reference Price over the Cap Price.

F6 · derivative.expiration_date: The Contracts are scheduled to mature evenly over a series of 20 valuation dates from June 1, 2026 to June 29, 2026, inclusive.

F7 · ownership.nature: As previously disclosed, including in the Schedule 13D filed by Walgreen Co. ("Walgreens") and others on April 15, 2014, as amended on January 16, 2015, January 25, 2016, March 22, 2016, August 25, 2016, November 14, 2016, January 6, 2021, June 3, 2021, May 12, 2022, August 4, 2022, November 9, 2022, December 12, 2022, May 15, 2023, June 20, 2023, August 7, 2023 and November 14, 2023, the Form 8-K filed by the Issuer on March 20, 2013, the Form 8-K filed by Walgreens on March 20, 2013, the Form 8-K filed by the Reporting Person on June 4, 2021 and the Form 8-K filed by the Issuer on June 2, 2021, the shares referenced in this Form 4 were acquired in accordance with the Framework Agreement, dated as of March 18, 2013 among Walgreens, Alliance Boots GmbH and the Issuer (the "Framework Agreement").

F8 · ownership.nature: These Contracts are held by Counterparty.

F9 · ownership.nature: As described in the Schedule 13D, as amended, WBA Investments, Inc., a direct wholly-owned subsidiary of the Reporting Person and the sole member of Counterparty, may also be deemed to beneficially own the securities reported in this Form 4.

SEC source: 0000899243-23-020341 · doc4.xml · derivative · entry 3

Walgreens Boots Alliance, Inc. · CIK 0001618921 · 10% owner

Walgreens Boots Alliance Holdings LLC · CIK 0001669077 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 540,000

Underlying: Common Stock · 540,000 shares

Expires not disclosed

F2 · derivative.exercise_price: On November 9, 2023, Walgreens Boots Alliance Holdings LLC ("Counterparty"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the "Reporting Person"), entered into variable pre-paid forward sale contracts (the "Contracts") with four unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 2,700,000 shares of common stock ("Common Stock") of Cencora, Inc. (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $423.9 million on or about the date of entering into the Contracts.

F3 · derivative.exercise_price: [continued from FN (2)] Counterparty also pledged 2,700,000 shares of Common Stock (the "Pledged Shares") in the aggregate to the financial institutions or their affiliates to secure its obligations under the Contracts and retained certain dividend and voting rights on the Pledged Shares. In respect of each valuation date under the Contracts, the aggregate number of shares of Common Stock to be delivered to the financial institutions or cash to be delivered to (or by) the financial institutions is to be determined as follows: Counterparty may, at its election, subject to certain conditions (1) be obligated to deliver to the financial institutions the full number of shares to which such valuation date relates and will receive an additional cash payment determined as follows:

F4 · derivative.exercise_price: [continued from FN (3)] (a) if the volume-weighted average price of the Common Stock on such valuation date (the "Reference Price") is less than or equal to $173.8838 (the "Floor Price"), the additional cash payment would be zero, (b) if the Reference Price is greater than the Floor Price but less than or equal to $224.6813 (the "Cap Price"), the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Reference Price over the Floor Price and (c) if the Reference Price is greater than the Cap Price, the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Cap Price over the Floor Price. Alternatively, (2) Counterparty may elect, subject to certain conditions, to not receive any additional cash payment and be obligated to deliver to the financial institutions in the aggregate a number of shares of Common Stock

F5 · derivative.exercise_price: [continued from FN (4)] (or the cash value thereof at the Reference Price) determined as follows: (a) if the Reference Price is less than or equal to the Floor Price, the full number of shares to which such valuation date relates, (b) if the Reference Price is greater than the Floor Price but less than or equal to the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the Floor Price and (c) if the Reference Price is greater than the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the sum of the Floor Price and the excess of the Reference Price over the Cap Price.

F6 · derivative.exercise_price: The Contracts are scheduled to mature evenly over a series of 20 valuation dates from June 1, 2026 to June 29, 2026, inclusive.

F2 · kind: On November 9, 2023, Walgreens Boots Alliance Holdings LLC ("Counterparty"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the "Reporting Person"), entered into variable pre-paid forward sale contracts (the "Contracts") with four unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 2,700,000 shares of common stock ("Common Stock") of Cencora, Inc. (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $423.9 million on or about the date of entering into the Contracts.

F2 · price: On November 9, 2023, Walgreens Boots Alliance Holdings LLC ("Counterparty"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the "Reporting Person"), entered into variable pre-paid forward sale contracts (the "Contracts") with four unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 2,700,000 shares of common stock ("Common Stock") of Cencora, Inc. (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $423.9 million on or about the date of entering into the Contracts.

F2 · derivative.exercise_date: On November 9, 2023, Walgreens Boots Alliance Holdings LLC ("Counterparty"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the "Reporting Person"), entered into variable pre-paid forward sale contracts (the "Contracts") with four unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 2,700,000 shares of common stock ("Common Stock") of Cencora, Inc. (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $423.9 million on or about the date of entering into the Contracts.

F3 · derivative.exercise_date: [continued from FN (2)] Counterparty also pledged 2,700,000 shares of Common Stock (the "Pledged Shares") in the aggregate to the financial institutions or their affiliates to secure its obligations under the Contracts and retained certain dividend and voting rights on the Pledged Shares. In respect of each valuation date under the Contracts, the aggregate number of shares of Common Stock to be delivered to the financial institutions or cash to be delivered to (or by) the financial institutions is to be determined as follows: Counterparty may, at its election, subject to certain conditions (1) be obligated to deliver to the financial institutions the full number of shares to which such valuation date relates and will receive an additional cash payment determined as follows:

F4 · derivative.exercise_date: [continued from FN (3)] (a) if the volume-weighted average price of the Common Stock on such valuation date (the "Reference Price") is less than or equal to $173.8838 (the "Floor Price"), the additional cash payment would be zero, (b) if the Reference Price is greater than the Floor Price but less than or equal to $224.6813 (the "Cap Price"), the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Reference Price over the Floor Price and (c) if the Reference Price is greater than the Cap Price, the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Cap Price over the Floor Price. Alternatively, (2) Counterparty may elect, subject to certain conditions, to not receive any additional cash payment and be obligated to deliver to the financial institutions in the aggregate a number of shares of Common Stock

F5 · derivative.exercise_date: [continued from FN (4)] (or the cash value thereof at the Reference Price) determined as follows: (a) if the Reference Price is less than or equal to the Floor Price, the full number of shares to which such valuation date relates, (b) if the Reference Price is greater than the Floor Price but less than or equal to the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the Floor Price and (c) if the Reference Price is greater than the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the sum of the Floor Price and the excess of the Reference Price over the Cap Price.

F6 · derivative.exercise_date: The Contracts are scheduled to mature evenly over a series of 20 valuation dates from June 1, 2026 to June 29, 2026, inclusive.

F2 · derivative.expiration_date: On November 9, 2023, Walgreens Boots Alliance Holdings LLC ("Counterparty"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the "Reporting Person"), entered into variable pre-paid forward sale contracts (the "Contracts") with four unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 2,700,000 shares of common stock ("Common Stock") of Cencora, Inc. (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $423.9 million on or about the date of entering into the Contracts.

F3 · derivative.expiration_date: [continued from FN (2)] Counterparty also pledged 2,700,000 shares of Common Stock (the "Pledged Shares") in the aggregate to the financial institutions or their affiliates to secure its obligations under the Contracts and retained certain dividend and voting rights on the Pledged Shares. In respect of each valuation date under the Contracts, the aggregate number of shares of Common Stock to be delivered to the financial institutions or cash to be delivered to (or by) the financial institutions is to be determined as follows: Counterparty may, at its election, subject to certain conditions (1) be obligated to deliver to the financial institutions the full number of shares to which such valuation date relates and will receive an additional cash payment determined as follows:

F4 · derivative.expiration_date: [continued from FN (3)] (a) if the volume-weighted average price of the Common Stock on such valuation date (the "Reference Price") is less than or equal to $173.8838 (the "Floor Price"), the additional cash payment would be zero, (b) if the Reference Price is greater than the Floor Price but less than or equal to $224.6813 (the "Cap Price"), the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Reference Price over the Floor Price and (c) if the Reference Price is greater than the Cap Price, the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Cap Price over the Floor Price. Alternatively, (2) Counterparty may elect, subject to certain conditions, to not receive any additional cash payment and be obligated to deliver to the financial institutions in the aggregate a number of shares of Common Stock

F5 · derivative.expiration_date: [continued from FN (4)] (or the cash value thereof at the Reference Price) determined as follows: (a) if the Reference Price is less than or equal to the Floor Price, the full number of shares to which such valuation date relates, (b) if the Reference Price is greater than the Floor Price but less than or equal to the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the Floor Price and (c) if the Reference Price is greater than the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the sum of the Floor Price and the excess of the Reference Price over the Cap Price.

F6 · derivative.expiration_date: The Contracts are scheduled to mature evenly over a series of 20 valuation dates from June 1, 2026 to June 29, 2026, inclusive.

F7 · ownership.nature: As previously disclosed, including in the Schedule 13D filed by Walgreen Co. ("Walgreens") and others on April 15, 2014, as amended on January 16, 2015, January 25, 2016, March 22, 2016, August 25, 2016, November 14, 2016, January 6, 2021, June 3, 2021, May 12, 2022, August 4, 2022, November 9, 2022, December 12, 2022, May 15, 2023, June 20, 2023, August 7, 2023 and November 14, 2023, the Form 8-K filed by the Issuer on March 20, 2013, the Form 8-K filed by Walgreens on March 20, 2013, the Form 8-K filed by the Reporting Person on June 4, 2021 and the Form 8-K filed by the Issuer on June 2, 2021, the shares referenced in this Form 4 were acquired in accordance with the Framework Agreement, dated as of March 18, 2013 among Walgreens, Alliance Boots GmbH and the Issuer (the "Framework Agreement").

F8 · ownership.nature: These Contracts are held by Counterparty.

F9 · ownership.nature: As described in the Schedule 13D, as amended, WBA Investments, Inc., a direct wholly-owned subsidiary of the Reporting Person and the sole member of Counterparty, may also be deemed to beneficially own the securities reported in this Form 4.

SEC source: 0000899243-23-020341 · doc4.xml · derivative · entry 2

Walgreens Boots Alliance, Inc. · CIK 0001618921 · 10% owner

Walgreens Boots Alliance Holdings LLC · CIK 0001669077 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 540,000

Underlying: Common Stock · 540,000 shares

Expires not disclosed

F2 · derivative.exercise_price: On November 9, 2023, Walgreens Boots Alliance Holdings LLC ("Counterparty"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the "Reporting Person"), entered into variable pre-paid forward sale contracts (the "Contracts") with four unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 2,700,000 shares of common stock ("Common Stock") of Cencora, Inc. (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $423.9 million on or about the date of entering into the Contracts.

F3 · derivative.exercise_price: [continued from FN (2)] Counterparty also pledged 2,700,000 shares of Common Stock (the "Pledged Shares") in the aggregate to the financial institutions or their affiliates to secure its obligations under the Contracts and retained certain dividend and voting rights on the Pledged Shares. In respect of each valuation date under the Contracts, the aggregate number of shares of Common Stock to be delivered to the financial institutions or cash to be delivered to (or by) the financial institutions is to be determined as follows: Counterparty may, at its election, subject to certain conditions (1) be obligated to deliver to the financial institutions the full number of shares to which such valuation date relates and will receive an additional cash payment determined as follows:

F4 · derivative.exercise_price: [continued from FN (3)] (a) if the volume-weighted average price of the Common Stock on such valuation date (the "Reference Price") is less than or equal to $173.8838 (the "Floor Price"), the additional cash payment would be zero, (b) if the Reference Price is greater than the Floor Price but less than or equal to $224.6813 (the "Cap Price"), the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Reference Price over the Floor Price and (c) if the Reference Price is greater than the Cap Price, the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Cap Price over the Floor Price. Alternatively, (2) Counterparty may elect, subject to certain conditions, to not receive any additional cash payment and be obligated to deliver to the financial institutions in the aggregate a number of shares of Common Stock

F5 · derivative.exercise_price: [continued from FN (4)] (or the cash value thereof at the Reference Price) determined as follows: (a) if the Reference Price is less than or equal to the Floor Price, the full number of shares to which such valuation date relates, (b) if the Reference Price is greater than the Floor Price but less than or equal to the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the Floor Price and (c) if the Reference Price is greater than the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the sum of the Floor Price and the excess of the Reference Price over the Cap Price.

F6 · derivative.exercise_price: The Contracts are scheduled to mature evenly over a series of 20 valuation dates from June 1, 2026 to June 29, 2026, inclusive.

F2 · kind: On November 9, 2023, Walgreens Boots Alliance Holdings LLC ("Counterparty"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the "Reporting Person"), entered into variable pre-paid forward sale contracts (the "Contracts") with four unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 2,700,000 shares of common stock ("Common Stock") of Cencora, Inc. (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $423.9 million on or about the date of entering into the Contracts.

F2 · price: On November 9, 2023, Walgreens Boots Alliance Holdings LLC ("Counterparty"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the "Reporting Person"), entered into variable pre-paid forward sale contracts (the "Contracts") with four unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 2,700,000 shares of common stock ("Common Stock") of Cencora, Inc. (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $423.9 million on or about the date of entering into the Contracts.

F2 · derivative.exercise_date: On November 9, 2023, Walgreens Boots Alliance Holdings LLC ("Counterparty"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the "Reporting Person"), entered into variable pre-paid forward sale contracts (the "Contracts") with four unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 2,700,000 shares of common stock ("Common Stock") of Cencora, Inc. (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $423.9 million on or about the date of entering into the Contracts.

F3 · derivative.exercise_date: [continued from FN (2)] Counterparty also pledged 2,700,000 shares of Common Stock (the "Pledged Shares") in the aggregate to the financial institutions or their affiliates to secure its obligations under the Contracts and retained certain dividend and voting rights on the Pledged Shares. In respect of each valuation date under the Contracts, the aggregate number of shares of Common Stock to be delivered to the financial institutions or cash to be delivered to (or by) the financial institutions is to be determined as follows: Counterparty may, at its election, subject to certain conditions (1) be obligated to deliver to the financial institutions the full number of shares to which such valuation date relates and will receive an additional cash payment determined as follows:

F4 · derivative.exercise_date: [continued from FN (3)] (a) if the volume-weighted average price of the Common Stock on such valuation date (the "Reference Price") is less than or equal to $173.8838 (the "Floor Price"), the additional cash payment would be zero, (b) if the Reference Price is greater than the Floor Price but less than or equal to $224.6813 (the "Cap Price"), the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Reference Price over the Floor Price and (c) if the Reference Price is greater than the Cap Price, the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Cap Price over the Floor Price. Alternatively, (2) Counterparty may elect, subject to certain conditions, to not receive any additional cash payment and be obligated to deliver to the financial institutions in the aggregate a number of shares of Common Stock

F5 · derivative.exercise_date: [continued from FN (4)] (or the cash value thereof at the Reference Price) determined as follows: (a) if the Reference Price is less than or equal to the Floor Price, the full number of shares to which such valuation date relates, (b) if the Reference Price is greater than the Floor Price but less than or equal to the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the Floor Price and (c) if the Reference Price is greater than the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the sum of the Floor Price and the excess of the Reference Price over the Cap Price.

F6 · derivative.exercise_date: The Contracts are scheduled to mature evenly over a series of 20 valuation dates from June 1, 2026 to June 29, 2026, inclusive.

F2 · derivative.expiration_date: On November 9, 2023, Walgreens Boots Alliance Holdings LLC ("Counterparty"), an indirect wholly owned subsidiary of Walgreens Boots Alliance, Inc. (the "Reporting Person"), entered into variable pre-paid forward sale contracts (the "Contracts") with four unaffiliated financial institutions. The Contracts obligate Counterparty to deliver to the financial institutions in the aggregate up to 2,700,000 shares of common stock ("Common Stock") of Cencora, Inc. (or, at Counterparty's election, an equivalent amount of cash based on the volume-weighted average price of the Common Stock) over a valuation period and may entitle Counterparty to an additional cash payment in respect of each valuation date of the Contracts. In exchange for assuming these obligations, Counterparty received cash payments from the financial institutions in an aggregate amount of approximately $423.9 million on or about the date of entering into the Contracts.

F3 · derivative.expiration_date: [continued from FN (2)] Counterparty also pledged 2,700,000 shares of Common Stock (the "Pledged Shares") in the aggregate to the financial institutions or their affiliates to secure its obligations under the Contracts and retained certain dividend and voting rights on the Pledged Shares. In respect of each valuation date under the Contracts, the aggregate number of shares of Common Stock to be delivered to the financial institutions or cash to be delivered to (or by) the financial institutions is to be determined as follows: Counterparty may, at its election, subject to certain conditions (1) be obligated to deliver to the financial institutions the full number of shares to which such valuation date relates and will receive an additional cash payment determined as follows:

F4 · derivative.expiration_date: [continued from FN (3)] (a) if the volume-weighted average price of the Common Stock on such valuation date (the "Reference Price") is less than or equal to $173.8838 (the "Floor Price"), the additional cash payment would be zero, (b) if the Reference Price is greater than the Floor Price but less than or equal to $224.6813 (the "Cap Price"), the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Reference Price over the Floor Price and (c) if the Reference Price is greater than the Cap Price, the additional cash payment would equal the number of shares of Common Stock to which such valuation date relates multiplied by the excess of the Cap Price over the Floor Price. Alternatively, (2) Counterparty may elect, subject to certain conditions, to not receive any additional cash payment and be obligated to deliver to the financial institutions in the aggregate a number of shares of Common Stock

F5 · derivative.expiration_date: [continued from FN (4)] (or the cash value thereof at the Reference Price) determined as follows: (a) if the Reference Price is less than or equal to the Floor Price, the full number of shares to which such valuation date relates, (b) if the Reference Price is greater than the Floor Price but less than or equal to the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the Floor Price and (c) if the Reference Price is greater than the Cap Price, a number of shares of Common Stock having a value (based on the Reference Price) equal to the number of shares of Common Stock to which such valuation date relates multiplied by the sum of the Floor Price and the excess of the Reference Price over the Cap Price.

F6 · derivative.expiration_date: The Contracts are scheduled to mature evenly over a series of 20 valuation dates from June 1, 2026 to June 29, 2026, inclusive.

F7 · ownership.nature: As previously disclosed, including in the Schedule 13D filed by Walgreen Co. ("Walgreens") and others on April 15, 2014, as amended on January 16, 2015, January 25, 2016, March 22, 2016, August 25, 2016, November 14, 2016, January 6, 2021, June 3, 2021, May 12, 2022, August 4, 2022, November 9, 2022, December 12, 2022, May 15, 2023, June 20, 2023, August 7, 2023 and November 14, 2023, the Form 8-K filed by the Issuer on March 20, 2013, the Form 8-K filed by Walgreens on March 20, 2013, the Form 8-K filed by the Reporting Person on June 4, 2021 and the Form 8-K filed by the Issuer on June 2, 2021, the shares referenced in this Form 4 were acquired in accordance with the Framework Agreement, dated as of March 18, 2013 among Walgreens, Alliance Boots GmbH and the Issuer (the "Framework Agreement").

F8 · ownership.nature: These Contracts are held by Counterparty.

F9 · ownership.nature: As described in the Schedule 13D, as amended, WBA Investments, Inc., a direct wholly-owned subsidiary of the Reporting Person and the sole member of Counterparty, may also be deemed to beneficially own the securities reported in this Form 4.

SEC source: 0000899243-23-020341 · doc4.xml · nonDerivative · entry 1

Walgreens Boots Alliance, Inc. · CIK 0001618921 · 10% owner

Walgreens Boots Alliance Holdings LLC · CIK 0001669077 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnotes

Disclosed balance after: 30,489,956

F1 · kind: Represents a sale in a private transaction to the Issuer by WBA Holdings.

F7 · balance_after: As previously disclosed, including in the Schedule 13D filed by Walgreen Co. ("Walgreens") and others on April 15, 2014, as amended on January 16, 2015, January 25, 2016, March 22, 2016, August 25, 2016, November 14, 2016, January 6, 2021, June 3, 2021, May 12, 2022, August 4, 2022, November 9, 2022, December 12, 2022, May 15, 2023, June 20, 2023, August 7, 2023 and November 14, 2023, the Form 8-K filed by the Issuer on March 20, 2013, the Form 8-K filed by Walgreens on March 20, 2013, the Form 8-K filed by the Reporting Person on June 4, 2021 and the Form 8-K filed by the Issuer on June 2, 2021, the shares referenced in this Form 4 were acquired in accordance with the Framework Agreement, dated as of March 18, 2013 among Walgreens, Alliance Boots GmbH and the Issuer (the "Framework Agreement").

F7 · ownership.nature: As previously disclosed, including in the Schedule 13D filed by Walgreen Co. ("Walgreens") and others on April 15, 2014, as amended on January 16, 2015, January 25, 2016, March 22, 2016, August 25, 2016, November 14, 2016, January 6, 2021, June 3, 2021, May 12, 2022, August 4, 2022, November 9, 2022, December 12, 2022, May 15, 2023, June 20, 2023, August 7, 2023 and November 14, 2023, the Form 8-K filed by the Issuer on March 20, 2013, the Form 8-K filed by Walgreens on March 20, 2013, the Form 8-K filed by the Reporting Person on June 4, 2021 and the Form 8-K filed by the Issuer on June 2, 2021, the shares referenced in this Form 4 were acquired in accordance with the Framework Agreement, dated as of March 18, 2013 among Walgreens, Alliance Boots GmbH and the Issuer (the "Framework Agreement").

F8 · ownership.nature: These Contracts are held by Counterparty.

F9 · ownership.nature: As described in the Schedule 13D, as amended, WBA Investments, Inc., a direct wholly-owned subsidiary of the Reporting Person and the sole member of Counterparty, may also be deemed to beneficially own the securities reported in this Form 4.

SEC source: 0001140859-23-000165 · wk-form4_1699911670.xml · derivative · entry 6

Donato Leslie E · CIK 0001784795 · EVP & Chief Strategy Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,049

Underlying: Common Stock · 3,049 shares

Expires not disclosed

F5 · derivative.exercise_price: Grant of restricted stock units received for no consideration that vests in three equal installments on 11/08/2024, 11/08/2025, and 11/08/2026.

F5 · price: Grant of restricted stock units received for no consideration that vests in three equal installments on 11/08/2024, 11/08/2025, and 11/08/2026.

F5 · derivative.exercise_date: Grant of restricted stock units received for no consideration that vests in three equal installments on 11/08/2024, 11/08/2025, and 11/08/2026.

F5 · derivative.expiration_date: Grant of restricted stock units received for no consideration that vests in three equal installments on 11/08/2024, 11/08/2025, and 11/08/2026.

SEC source: 0001140859-23-000169 · wk-form4_1699911957.xml · derivative · entry 6

Mauch Robert P. · CIK 0001633897 · Executive Vice President & COO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,196

Underlying: Common Stock · 12,196 shares

Expires not disclosed

F5 · derivative.exercise_price: Grant of restricted stock units received for no consideration that vests in three equal installments on 11/08/2024, 11/08/2025, and 11/08/2026.

F5 · price: Grant of restricted stock units received for no consideration that vests in three equal installments on 11/08/2024, 11/08/2025, and 11/08/2026.

F5 · derivative.exercise_date: Grant of restricted stock units received for no consideration that vests in three equal installments on 11/08/2024, 11/08/2025, and 11/08/2026.

F5 · derivative.expiration_date: Grant of restricted stock units received for no consideration that vests in three equal installments on 11/08/2024, 11/08/2025, and 11/08/2026.

SEC source: 0001140859-23-000167 · wk-form4_1699911803.xml · derivative · entry 6

Krikorian Lazarus · CIK 0001627534 · SVP & Chief Accounting Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,193

Underlying: Common Stock · 4,193 shares

Expires not disclosed

F5 · derivative.exercise_price: Grant of restricted stock units received for no consideration that vests in three equal installments on 11/08/2024, 11/08/2025, and 11/08/2026.

F5 · price: Grant of restricted stock units received for no consideration that vests in three equal installments on 11/08/2024, 11/08/2025, and 11/08/2026.

F5 · derivative.exercise_date: Grant of restricted stock units received for no consideration that vests in three equal installments on 11/08/2024, 11/08/2025, and 11/08/2026.

F5 · derivative.expiration_date: Grant of restricted stock units received for no consideration that vests in three equal installments on 11/08/2024, 11/08/2025, and 11/08/2026.

SEC source: 0001140859-23-000163 · wk-form4_1699911532.xml · derivative · entry 6

COLLIS STEVEN H · CIK 0001191508 · Director · Chairman, President & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,408

Underlying: Common Stock · 25,408 shares

Expires not disclosed

F5 · price: Grant of restricted stock units received for no consideration that vests in three equal installments on 11/08/2024, 11/08/2025, and 11/08/2026.

F5 · derivative.exercise_date: Grant of restricted stock units received for no consideration that vests in three equal installments on 11/08/2024, 11/08/2025, and 11/08/2026.

F5 · derivative.expiration_date: Grant of restricted stock units received for no consideration that vests in three equal installments on 11/08/2024, 11/08/2025, and 11/08/2026.

SEC source: 0001140859-23-000161 · wk-form4_1699911415.xml · derivative · entry 6

Cleary James F · CIK 0001333281 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,318

Underlying: Common Stock · 7,318 shares

Expires not disclosed

F5 · derivative.exercise_price: Grant of restricted stock units received for no consideration that vests in three equal installments on 11/08/2024, 11/08/2025, and 11/08/2026.

F5 · price: Grant of restricted stock units received for no consideration that vests in three equal installments on 11/08/2024, 11/08/2025, and 11/08/2026.

F5 · derivative.exercise_date: Grant of restricted stock units received for no consideration that vests in three equal installments on 11/08/2024, 11/08/2025, and 11/08/2026.

F5 · derivative.expiration_date: Grant of restricted stock units received for no consideration that vests in three equal installments on 11/08/2024, 11/08/2025, and 11/08/2026.

SEC source: 0001140859-23-000159 · wk-form4_1699911245.xml · derivative · entry 6

Clark Gina · CIK 0001625811 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,253

Underlying: Common Stock · 3,253 shares

Expires not disclosed

F5 · derivative.exercise_price: Grant of restricted stock units received for no consideration that vests in three equal installments on 11/08/2024, 11/08/2025, and 11/08/2026.

F5 · price: Grant of restricted stock units received for no consideration that vests in three equal installments on 11/08/2024, 11/08/2025, and 11/08/2026.

F5 · derivative.exercise_date: Grant of restricted stock units received for no consideration that vests in three equal installments on 11/08/2024, 11/08/2025, and 11/08/2026.

F5 · derivative.expiration_date: Grant of restricted stock units received for no consideration that vests in three equal installments on 11/08/2024, 11/08/2025, and 11/08/2026.

SEC source: 0001140859-23-000157 · wk-form4_1699911063.xml · derivative · entry 6

Campbell Elizabeth S · CIK 0001882641 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,489

Underlying: Common Stock · 5,489 shares

Expires not disclosed

F5 · derivative.exercise_price: Grant of restricted stock units received for no consideration that vests in three equal installments on 11/08/2024, 11/08/2025, and 11/08/2026.

F5 · price: Grant of restricted stock units received for no consideration that vests in three equal installments on 11/08/2024, 11/08/2025, and 11/08/2026.

F5 · derivative.exercise_date: Grant of restricted stock units received for no consideration that vests in three equal installments on 11/08/2024, 11/08/2025, and 11/08/2026.

F5 · derivative.expiration_date: Grant of restricted stock units received for no consideration that vests in three equal installments on 11/08/2024, 11/08/2025, and 11/08/2026.

SEC source: 0001140859-23-000155 · wk-form4_1699910900.xml · derivative · entry 6

Battaglia Silvana · CIK 0001774724 · Executive Vice President

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,253

Underlying: Common Stock · 3,253 shares

Expires not disclosed

F5 · derivative.exercise_price: Grant of restricted stock units received for no consideration that vests in three equal installments on 11/08/2024, 11/08/2025, and 11/08/2026.

F5 · price: Grant of restricted stock units received for no consideration that vests in three equal installments on 11/08/2024, 11/08/2025, and 11/08/2026.

F5 · derivative.exercise_date: Grant of restricted stock units received for no consideration that vests in three equal installments on 11/08/2024, 11/08/2025, and 11/08/2026.

F5 · derivative.expiration_date: Grant of restricted stock units received for no consideration that vests in three equal installments on 11/08/2024, 11/08/2025, and 11/08/2026.

SEC source: 0001140859-23-000153 · wk-form4_1699042374.xml · nonDerivative · entry 2

Baumann Werner · CIK 0001986505 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 614

F2 · shares: Grant of Restricted Stock Units issued in lieu of $25,000 quarterly cash retainer per the Registrant's Non-Employee Director Compensation Program. Delivery of vested shares deferred until 01/15/28.

F2 · price: Grant of Restricted Stock Units issued in lieu of $25,000 quarterly cash retainer per the Registrant's Non-Employee Director Compensation Program. Delivery of vested shares deferred until 01/15/28.

SEC source: 0001140859-23-000153 · wk-form4_1699042374.xml · nonDerivative · entry 1

Baumann Werner · CIK 0001986505 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 480

F1 · shares: Grant of Restricted Stock Units received for no consideration and vests 100% on the first anniversary of the date of the grant. Delivery of vested shares deferred until 01/15/28.

F1 · price: Grant of Restricted Stock Units received for no consideration and vests 100% on the first anniversary of the date of the grant. Delivery of vested shares deferred until 01/15/28.

SEC source: 0001140859-23-000151 · wk-form4_1699042255.xml · nonDerivative · entry 2

Tyler Lauren M · CIK 0001765744 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 614

F2 · shares: Grant of Restricted Stock Units issued in lieu of $25,000 quarterly cash retainer per the Registrant's Non-Employee Director Compensation Program. Delivery of vested shares deferred until 10/31/33.

F2 · price: Grant of Restricted Stock Units issued in lieu of $25,000 quarterly cash retainer per the Registrant's Non-Employee Director Compensation Program. Delivery of vested shares deferred until 10/31/33.

SEC source: 0001140859-23-000151 · wk-form4_1699042255.xml · nonDerivative · entry 1

Tyler Lauren M · CIK 0001765744 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 480

F1 · shares: Grant of Restricted Stock Units received for no consideration and vests 100% on the first anniversary of the date of the grant. Delivery of vested shares deferred until 10/31/33.

F1 · price: Grant of Restricted Stock Units received for no consideration and vests 100% on the first anniversary of the date of the grant. Delivery of vested shares deferred until 10/31/33.

SEC source: 0001140859-23-000149 · wk-form4_1699042144.xml · nonDerivative · entry 1

NALLY DENNIS M · CIK 0001685596 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,251

F1 · shares: Shares of common stock issued in lieu of $31,250 quarterly cash retainer per the terms of the Registrant's Non-Employee Director Compensation Program.

SEC source: 0001140859-24-000083 · wk-form4_1715371212.xml · nonDerivative · entry 1

GREENBERG LON R · CIK 0001234234 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,062

F1 · kind: Gift to charitable trust.

SEC source: 0001140859-23-000144 · wk-form4_1697055628.xml · derivative · entry 3

COLLIS STEVEN H · CIK 0001191508 · Director · Chairman, President & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 25,000 shares

Expires 2024-11-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: Exercisable in four equal installments on 11/15/18, 11/15/19, 11/15/20 and 11/15/21.

SEC source: 0001140859-23-000144 · wk-form4_1697055628.xml · nonDerivative · entry 2

COLLIS STEVEN H · CIK 0001191508 · Director · Chairman, President & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 257,967

F1 · shares: The sale of stock reflected in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the reporting person effective 12/13/2022 and disclosed in the Company's Form 8-K filed with the Securities and Exchange Commission on 12/16/2022.

SEC source: 0001140859-23-000144 · wk-form4_1697055628.xml · nonDerivative · entry 1

COLLIS STEVEN H · CIK 0001191508 · Director · Chairman, President & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 282,967

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: The sale of stock reflected in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the reporting person effective 12/13/2022 and disclosed in the Company's Form 8-K filed with the Securities and Exchange Commission on 12/16/2022.

SEC source: 0001140859-23-000142 · wk-form4_1697055530.xml · nonDerivative · entry 1

Clark Gina · CIK 0001625811 · Executive Vice President

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 16,038

F1 · shares: The sale of stock reflected in this Form 4 was effected pursuant to a 10b5-1 trading plan entered into by the reporting person dated 6/22/2023.

SEC source: 0001140859-23-000136 · wk-form4_1695845331.xml · nonDerivative · entry 1

Mauch Robert P. · CIK 0001633897 · Executive Vice President & COO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 23,687

F1 · shares: The sale of stock reflected in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the reporting person dated 6/26/2023.

SEC source: 0001140859-23-000134 · wk-form4_1695845184.xml · derivative · entry 3

Clark Gina · CIK 0001625811 · Executive Vice President

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 20,971 shares

Expires 2025-11-14

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: Exercisable in four equal annual installments on 11/14/19, 11/14/20, 11/14/21 and 11/14/22.

SEC source: 0001140859-23-000134 · wk-form4_1695845184.xml · nonDerivative · entry 2

Clark Gina · CIK 0001625811 · Executive Vice President

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 26,733

F1 · shares: The sale of stock reflected in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the reporting person dated 6/22/2023.

SEC source: 0001140859-23-000134 · wk-form4_1695845184.xml · nonDerivative · entry 1

Clark Gina · CIK 0001625811 · Executive Vice President

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 47,704

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: The sale of stock reflected in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the reporting person dated 6/22/2023.

SEC source: 0001140859-23-000132 · wk-form4_1695412993.xml · derivative · entry 3

Donato Leslie E · CIK 0001784795 · EVP & Chief Strategy Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 3,387

Underlying: Common Stock · 3,386 shares

Expires 2026-11-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: The sale of stock reflected in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the reporting person dated May 26, 2023.

F2 · derivative.exercise_date: Exercisable in four equal annual installments on 11/13/20, 11/13/21, 11/13/22 and 11/13/23.

SEC source: 0001140859-23-000132 · wk-form4_1695412993.xml · nonDerivative · entry 2

Donato Leslie E · CIK 0001784795 · EVP & Chief Strategy Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 5,349.752

F1 · shares: The sale of stock reflected in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the reporting person dated May 26, 2023.

SEC source: 0001140859-23-000132 · wk-form4_1695412993.xml · nonDerivative · entry 1

Donato Leslie E · CIK 0001784795 · EVP & Chief Strategy Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 8,735.752

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: The sale of stock reflected in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the reporting person dated May 26, 2023.

SEC source: 0001140859-23-000130 · wk-form4_1694635771.xml · derivative · entry 3

COLLIS STEVEN H · CIK 0001191508 · Director · Chairman, President & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 75,000

Underlying: Common Stock · 10,500 shares

Expires 2024-11-15

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: Exercisable in four equal installments on 11/15/18, 11/15/19, 11/15/20 and 11/15/21.

SEC source: 0001140859-23-000130 · wk-form4_1694635771.xml · nonDerivative · entry 2

COLLIS STEVEN H · CIK 0001191508 · Director · Chairman, President & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 257,967

F1 · shares: The sale of stock reflected in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the reporting person effective 12/13/2022 and disclosed in the Company's Form 8-K filed with the Securities and Exchange Commission on 12/16/2022.

SEC source: 0001140859-23-000130 · wk-form4_1694635771.xml · nonDerivative · entry 1

COLLIS STEVEN H · CIK 0001191508 · Director · Chairman, President & CEO

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 268,467

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: The sale of stock reflected in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the reporting person effective 12/13/2022 and disclosed in the Company's Form 8-K filed with the Securities and Exchange Commission on 12/16/2022.

SEC source: 0001140859-23-000128 · wk-form4_1694116810.xml · derivative · entry 8

Donato Leslie E · CIK 0001784795 · EVP & Chief Strategy Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 6,773

Underlying: Common Stock · 1,845 shares

Expires 2026-11-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: The sale of stock reflected in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the reporting person dated May 26, 2023.

F2 · derivative.exercise_date: Exercisable in four equal annual installments on 11/13/20, 11/13/21, 11/13/22 and 11/13/23.

SEC source: 0001140859-23-000128 · wk-form4_1694116810.xml · nonDerivative · entry 6

Donato Leslie E · CIK 0001784795 · EVP & Chief Strategy Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 5,349.752

F1 · shares: The sale of stock reflected in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the reporting person dated May 26, 2023.

SEC source: 0001140859-23-000128 · wk-form4_1694116810.xml · nonDerivative · entry 5

Donato Leslie E · CIK 0001784795 · EVP & Chief Strategy Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 7,194.752

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: The sale of stock reflected in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the reporting person dated May 26, 2023.

SEC source: 0001140859-23-000128 · wk-form4_1694116810.xml · derivative · entry 7

Donato Leslie E · CIK 0001784795 · EVP & Chief Strategy Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 8,618

Underlying: Common Stock · 4,929 shares

Expires 2026-11-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: The sale of stock reflected in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the reporting person dated May 26, 2023.

F2 · derivative.exercise_date: Exercisable in four equal annual installments on 11/13/20, 11/13/21, 11/13/22 and 11/13/23.

SEC source: 0001140859-23-000128 · wk-form4_1694116810.xml · nonDerivative · entry 4

Donato Leslie E · CIK 0001784795 · EVP & Chief Strategy Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 5,349.752

F1 · shares: The sale of stock reflected in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the reporting person dated May 26, 2023.

SEC source: 0001140859-23-000128 · wk-form4_1694116810.xml · nonDerivative · entry 3

Donato Leslie E · CIK 0001784795 · EVP & Chief Strategy Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 10,278.752

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: The sale of stock reflected in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the reporting person dated May 26, 2023.

SEC source: 0001140859-23-000128 · wk-form4_1694116810.xml · nonDerivative · entry 2

Donato Leslie E · CIK 0001784795 · EVP & Chief Strategy Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 5,349.752

F1 · shares: The sale of stock reflected in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the reporting person dated May 26, 2023.

SEC source: 0001140859-23-000128 · wk-form4_1694116810.xml · nonDerivative · entry 1

Donato Leslie E · CIK 0001784795 · EVP & Chief Strategy Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 6,247.752

F1 · shares: The sale of stock reflected in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into by the reporting person dated May 26, 2023.